Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo ...
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
Novo Nordisk A/S was cited for quality lapses at a drug production plant in Denmark that makes the hit medicines Ozempic and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback